GSK questioned on corporate tax avoidance in Australia..

wouldn’t be the first time..

Nine major drug makers are being questioned about their tax minimisation strategies at a Senate committee hearing today after data showed they allegedly only paid a combined $85 million in tax out of $8.2 billion in revenue.

The powerful Senate Economics References Committee is focusing on revenue big pharmaceutical firms derive from the Government-funded pharmaceutical benefits scheme (PBS).

Companies including Pfizer, AstraZeneca, Novartis, Merck Sharp & Dohme and GlaxoSmithKline are be questioned at the hearing in Sydney about profit-shifting techniques through transfer pricing and royalty payments to subsidiaries in other countries.

The senate committee has received official data showing that between the nine companies more than $3.5 billion was received from PBS funding in 2014.

Of $8.2 billion in total revenue, it is claimed the companies paid tax of $85 million, which equates to a 1 per cent tax rate.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s